A recent trickle of mergers and acquisitions (M&A) announcements in the billion-dollar-and-up range suggests that biopharma may be ready to resume dealmaking this year—although the value and number of ...

When it comes to biopharma deals, 2022 has picked up where 2021 left off in one key respect: Companies are much more inclined to deploy capital expanding pipelines and building up their businesses ...

-- The EY-Parthenon brand now represents the entire EY Strategy and Transactions practice to support a comprehensive end-to-end client experience -- EY reaches new milestone with All in strategy, ...